Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.

about

Rare occurrence of inflammatory bowel disease in a cohort of Han Chinese ankylosing spondylitis patients- a single institute study.Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives.

P2860

Q42377151-EFE2770F-066B-4151-887D-414CA10D71AA Q54961768-92DA01FD-A2EA-4802-A85E-E80F9F47C60D

P2860

Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.

Item

http://www.wikidata.org/entity/Q38818978

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Adalimumab for Moderately to S ...... atic Review and Meta-Analysis.

@en

type

Item

label

Adalimumab for Moderately to S ...... atic Review and Meta-Analysis.

@en

prefLabel

Adalimumab for Moderately to S ...... atic Review and Meta-Analysis.

@en

P1476

Adalimumab for Moderately to S ...... matic Review and Meta-Analysis

@en

P2093

Bin Chen

http://www.w3.org/2001/XMLSchema#string

Chaoyuan Huang

http://www.w3.org/2001/XMLSchema#string

Chuanwei Mo

http://www.w3.org/2001/XMLSchema#string

Fengbin Liu

http://www.w3.org/2001/XMLSchema#string

Haiwen Li

http://www.w3.org/2001/XMLSchema#string

Jiangtao Hou

http://www.w3.org/2001/XMLSchema#string

Qian Xu

http://www.w3.org/2001/XMLSchema#string

Tianwen Liu

http://www.w3.org/2001/XMLSchema#string

Weiling He

http://www.w3.org/2001/XMLSchema#string

Xinlin Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

Epidemiology and natural history of inflammatory bowel diseases

Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities.

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis.

Efficacy and safety of adalimumab for the Crohn's disease: a systematic review and meta-analysis of published randomized placebo-controlled trials.

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis.

P2888

s40259-016-0173-6

P304

207-217

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.1007/S40259-016-0173-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yujie Yuan

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27120055

http://www.w3.org/2001/XMLSchema#string

P921

adalimumab

Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.

about

P2860

P2860

Adalimumab for Moderately to Severely Active Ulcerative Colitis: A Systematic Review and Meta-Analysis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921